Separate Q1 2026 revenue KRW 32.1B (YoY +84%), operating profit KRW 0.41B (vs loss KRW 1.78B a year ago), net loss KRW 0.21B (vs loss KRW 2.26B a year ago)
Adjusted debt ratio 173.75%, still high but not capital-impaired (total equity KRW 29.5B)
Listed company subject to substantive delisting review due to former largest shareholder's embezzlement/breach of trust; improvement period granted until July 12, 2026; delisting risk remains
Multiple lawsuits pending including damage claims against former largest shareholder (total approx. KRW 55.4B)
Long-term growth driven by donepezil patch licensing deals (Celltrion, Menarini, etc.) and strong cosmetics ODM performance